Loading clinical trials...
Loading clinical trials...
The study purpose is to investigate plasma HIV-1 RNA dynamics in subjects initiating raltegravir-based salvage therapy and quantify the corresponding changes in levels of cellular HIV-1 DNA.
First- and second-phase decay rates of plasma HIV-1 RNA and changes in the intracellular levels of HIV-1 proviral DNA and LTR circles will be measured in subjects starting salvage antiretroviral therapy including raltegravir in Spain.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Hospital U. Germans Trias i Pujol
Badalona, Barcelona, Spain
Start Date
June 1, 2008
Primary Completion Date
April 1, 2009
Completion Date
October 1, 2009
Last Updated
December 4, 2019
15
ACTUAL participants
Salvage antiretroviral therapy including raltegravir
DRUG
Lead Sponsor
Germans Trias i Pujol Hospital
Collaborators
NCT04142047
NCT06694805
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07428330